Next Article in Journal
(Semi)-Synthetic Fucosylated Chondroitin Sulfate Oligo- and Polysaccharides
Previous Article in Journal
Absorption and Tissue Distribution of Siphonaxanthin from Green Algae
Previous Article in Special Issue
Antioxidant, Hypolipidemic and Hepatic Protective Activities of Polysaccharides from Phascolosoma esculenta
Open AccessReview

Effect of Omega-3 Polyunsaturated Fatty Acids Treatment on Lipid Pattern of HIV Patients: A Meta-Analysis of Randomized Clinical Trials

1
Atherosclerosis and Hypertension Research Group, Medical and Surgical Sciences Department, Sant’Orsola-Malpighi University Hospital, Building 2–IV Floor, Via Albertoni 15, 40138 Bologna, Italy
2
Italian Nutraceutical Society (SINut), 40138 Bologna, Italy
*
Author to whom correspondence should be addressed.
These authors equally contributed to this work.
Mar. Drugs 2020, 18(6), 292; https://doi.org/10.3390/md18060292
Received: 8 May 2020 / Revised: 20 May 2020 / Accepted: 25 May 2020 / Published: 1 June 2020
(This article belongs to the Special Issue Marine-Derived Anti-Hyperlipidemic Drugs)
Even though omega-3 polyunsaturated fatty acids (PUFAs) seem to be effective in the treatment of human immunodeficiency virus (HIV)-associated dyslipidemia, their impact is still debated. For this reason, our aim was to perform a meta-analysis of the clinical evidence available to date. A systematic literature search was conducted in order to identify published clinical trials assessing the effect of PUFAs treatment on serum lipoproteins, and its safety profile. The effect sizes for lipid changes were expressed as mean difference (MD) and 95% confidence interval (CI). For safety analysis, odd ratios and the 95% CI were calculated with the Mantel–Haenszel method. Data were pooled from nine clinical studies comprising overall 578 HIV-affected subjects. Meta-analysis of the data suggested that omega-3 PUFAs significantly reduced triglycerides (TG) (MD = −1.04, 95% CI: −1.5, −0.58 mmol/L, p < 0.001), while increasing high-density lipoprotein cholesterol (MD = 0.36, 95% CI: 0.12, 0.61 mmol/L, p = 0.004), without affecting serum levels of total cholesterol, very-low- and low-density lipoprotein cholesterol, and apolipoprotein B and A1. Change in TG was significantly associated with eicosapentaenoic acid administered via daily dose. PUFA treatment did not lead to an increased risk of adverse events. In conclusion, PUFAs are safe and exert a significant plasma lipid improving effect in HIV-positive patients. View Full-Text
Keywords: HIV; Omega-3 polyunsaturated fatty acids; triglycerides; high-density lipoprotein cholesterol; meta-analysis HIV; Omega-3 polyunsaturated fatty acids; triglycerides; high-density lipoprotein cholesterol; meta-analysis
Show Figures

Figure 1

MDPI and ACS Style

Fogacci, F.; Strocchi, E.; Veronesi, M.; Borghi, C.; Cicero, A.F.G. Effect of Omega-3 Polyunsaturated Fatty Acids Treatment on Lipid Pattern of HIV Patients: A Meta-Analysis of Randomized Clinical Trials. Mar. Drugs 2020, 18, 292.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop